



## **Recombinant antivenoms based on mixtures of human antibodies against *D. jamesoni* toxins**

**Pus, Urska; Harrison, Robert; Andersen, Mikael Rørdam; Casewell, Nicholas; Laustsen, Andreas Hougaard**

*Publication date:*  
2016

*Document Version*  
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

*Citation (APA):*  
Pus, U., Harrison, R., Andersen, M. R., Casewell, N., & Laustsen, A. H. (2016). *Recombinant antivenoms based on mixtures of human antibodies against D. jamesoni toxins*. Poster session presented at Symposium for Biological and Life Science Students 2016, Cambridge, United Kingdom.

---



### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.





# Recombinant antivenoms based on mixtures of human antibodies against *D. jamesoni* toxins

Urska Pus<sup>1</sup>, Mikael R. Andersen<sup>1</sup>, Robert Harrison<sup>2</sup>, Nicholas Casewell<sup>2</sup>, Andreas H. Laustsen<sup>1</sup>

<sup>1</sup>Department of Biotechnology and Biomedicine, Technical University of Denmark

<sup>2</sup>Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

## The pressing problem of a snakebite

Each year, more than 5 million people worldwide are affected by a snakebite, resulting in 150,000 deaths, and 400,000 amputations<sup>1</sup>. The current medical treatment against envenoming is based on the administration of an animal-derived antiserum, containing antibodies against snake venom toxins. Due to the heterologous and immunogenic nature of antivenom, patients in up to 80% of the cases experience serum sickness and anaphylaxis, which in some cases leads to death<sup>2, 3</sup>.



## Clinical manifestations of *D. jamesoni* toxins

Early clinical signs


- Paralysis
- Fasciculation
- Vertigo
- Ataxia
- Sudden loss of consciousness

Late clinical signs


- Shock
- Hypotension
- Abdominal pain
- Epistaxis
- Pallor
- Increased sweating
- Nausea

Local tissue damage appears to be relatively infrequent and of minor severity in most cases, whereas the accumulative effect of symptoms may lead to death if not treated<sup>4</sup>.


## Toxicovenomics




## Selection of scFvs by phage display



## Format conversion of scFv to IgG



## Production of recombinant antibody mixtures



## Perspectives

This project aims to develop a fully recombinant snakebite antivenom against the potent venom of *D. jamesoni*. This antivenom will be based on selected human IgG antibodies, compatible with the human immune system and with proven specificity. It is the ambition of this project to contribute to the development of safer, more effective, and inexpensive treatment options against snakebite envenoming.

## References

- [1] WHO, <http://www.who.int/mediacentre/factsheets/fs337/en/>
- [2] Gutierrez JM, Leon G, Lomonte B, Angulo Y. (2011) Antivenoms for snakebite envenomings. *Inflammation & Allergy-Drug Targets* 10(5): 369-80.
- [3] World Health Organization W. WHO guidelines for the production, control and regulation of snake antivenom immunoglobulins. Geneva: WHO, 2010; 134.
- [4] UCSD, <http://toxicology.ucsd.edu/Snakebite%20Protocols/Dendroa2.htm>

## Contact information

DTU Bioengineering  
Technical University of Denmark  
Søltofts Plads 223  
DK-2800 Kgs. Lyngby, Denmark  
rbc389@alumni.ku.dk / (+386) 31 777 372

## Acknowledgements

We thank the Novo Nordisk Foundation (NNF16OC0019248) and Symphogen A/S for financial support.